Changes

no edit summary
Line 109: Line 109:  
PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549  
 
PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549  
 
|-
 
|-
 +
|
 +
|Classic ependymoma (no WHO grade assigned)
 +
|'''Gain:''' 1q, 5, 7, 9, 11, 18, 20<br>
 +
'''Loss:''' 1p, 3, -6/6q, 9p, 13q, 17, 22
 +
|Usually intracranial, spinal tumors (myxopapillary) are rare; 80% of pediatric tumors develop in posterior fossa (PF); Supratentorial tumors preferentially show monosomy 9; 1q gain is unfavorable prognostic indicator in PF tumors; spinal tumors associated with NF2 (germline); children have worse outcomes than adults
 +
|PMID:25965575; PMID:22338015; PMID:28371821
 +
|-
 +
|
 +
|Subependymoma, WHO grade I
 +
|Typically '''balanced genomes'''<br>
 +
'''Loss:''' -6/6q in spinal tumors
 +
|No diagnostic mutations
 +
|Favorable prognosis
 +
|WHO CNS Tumors (2016) <br>
 +
PMID:21959044; PMID:21840481<br>
 +
|-
 +
|
 +
|Myxopapillary ependymoma, WHO grade I
 +
|'''Aneuploidy:''' multiple chromosomes lost and gained
 +
|'''Mutation:''' NF2 (including germline) in spinal tumors
 +
|Less common but more aggressive in children
 +
|PMID:25965575; PMCID:3991130; PMID:20425037; PMID:25957288; PMID:25965575; PMID:22516549
 +
|-
 +
|
 +
|